1. Introduction

The regulation of vulnerable population inclusion in genetic research in Morocco involves the legal, ethical, medical and institutional safeguards governing the participation of individuals who may be particularly susceptible to exploitation, discrimination, coercion or violations of privacy.

Genetic research includes activities such as:

DNA sequencing and genetic profiling.

Research into hereditary and rare diseases.

Population genetics and ancestry studies.

Genetic screening of newborns and children.

Research involving pregnant women and embryos.

Genetic research involving persons with disabilities.

Studies involving economically disadvantaged communities.

Research involving refugees, migrants and individuals with limited decision-making capacity.

Vulnerable populations must not automatically be excluded from genetic research. Their participation may be scientifically and socially important, particularly where research concerns diseases disproportionately affecting particular communities. However, their inclusion requires additional safeguards to ensure voluntary participation, informed consent, confidentiality, equitable selection and protection against discrimination.

In Morocco, this subject must be examined through the country's biomedical research framework, personal-data protection legislation, constitutional guarantees, medical ethics and international human-rights obligations.

A central legal distinction is that protection of vulnerable participants does not mean denying them access to the potential benefits of scientific research. The objective is responsible and equitable inclusion.

2. Legal framework governing genetic research in Morocco

A. Law No. 28-13 of 2015: Protection of persons participating in biomedical research

The most directly relevant legislation is Morocco's Law No. 28-13 concerning the protection of persons participating in biomedical research, published in Official Gazette No. 6388 on 20 August 2015.

It establishes fundamental principles governing research involving human participants.

Article 3 recognizes principles including:

Respect for human life and health.

Protection of physical and psychological integrity.

Respect for human dignity and privacy.

Voluntary participation.

Free, informed and explicit consent.

Protection against commercial exploitation of the human body.

Compliance with appropriate standards of biomedical research.

These principles are particularly important in genetic research because genetic information can reveal hereditary diseases, family relationships, ancestry and potential health risks.

The law therefore provides a foundation for protecting individuals whose social, economic, medical or psychological circumstances may make them vulnerable to exploitation.

Ma Loi+1

B. Article 12: Protection of minors and legally protected adults

Article 12 is particularly significant.

It provides that biomedical research involving minors or adults subject to legal protection is generally permissible only where a direct health benefit is expected.

Research without a direct therapeutic benefit may nevertheless be permitted where:

It presents no serious foreseeable risk to the participant's health.

It is useful to persons having similar characteristics of age, illness or disability.

It cannot be conducted through other means.

The legally required consent safeguards are satisfied.

Where the participant is capable of expressing their wishes, their own consent must also be obtained. A participant's refusal or withdrawal of consent cannot simply be overridden by the legal representative.

This provision is important for genetic studies involving children with rare hereditary disorders, persons with intellectual disabilities and individuals who are legally protected.

Ma Loi

C. Article 16: Exclusion of certain populations

Article 16 prohibits biomedical research involving:

Persons deprived of liberty by judicial decision.

Persons involuntarily hospitalized.

This is an important restriction because individuals in detention or involuntary hospitalization may experience institutional pressure or may be unable to exercise genuinely independent choice.

For genetic research, this means researchers cannot treat institutional availability of participants as sufficient justification for recruitment.

Ma Loi+1

D. Articles 17, 18 and 22: Regional ethics committees

The law establishes regional committees responsible for examining biomedical research projects.

Their membership is intended to reflect multidisciplinary expertise, including:

Medical and biological sciences.

Pharmaceutical sciences.

Ethics.

Social sciences.

Psychology.

Religious considerations.

Law.

Article 22 requires the research sponsor to submit the research protocol to the competent regional committee before implementation.

The committee considers the scientific justification, risk-benefit assessment, recruitment procedures, informed-consent arrangements and the justification for involving persons unable to consent independently.

For genetic research involving vulnerable communities, this review should consider whether the research design is scientifically justified and whether the proposed safeguards are sufficient.

Ma Loi+1

3. Protection of genetic information under Law No. 09-08

Morocco's Law No. 09-08 of 18 February 2009 regulates the protection of personal data.

It is especially important because Article 1 expressly includes genetic information within sensitive personal data.

Important legal provisions:

Consequently, genetic researchers must consider both the biomedical research authorization framework and the separate data-protection requirements.

The National Commission for the Control of Personal Data Protection (CNDP) has an important supervisory role.

For example, a research institution collecting DNA samples from disadvantaged rural communities should explain:

Why the samples are being collected.

Whether whole-genome sequencing will be performed.

Whether samples will be stored for future research.

Whether information will be shared with foreign institutions.

Whether genetic information will be identifiable or pseudonymized.

How participants can exercise their applicable data-protection rights.

A participant's agreement to provide a blood sample for one medical study should not automatically be treated as unrestricted permission to use their genetic information for unrelated commercial or population-profiling projects.

BDJ+1

4. Special protection for different vulnerable populations

A. Children and newborns

Children are particularly vulnerable because they cannot always understand the implications of genetic testing.

For example, newborn genomic screening may reveal:

Inherited metabolic disorders.

Genetic susceptibility to cancer.

Future neurological conditions.

Carrier status for hereditary diseases.

Genetic conditions affecting reproductive health later in life.

Under Article 12 of Law 28-13, researchers must satisfy the special conditions governing research on minors.

The legal and ethical safeguards should include parental or legal-representative consent, age-appropriate explanations, respect for the child's developing autonomy and careful consideration of whether testing should reveal conditions that may not become relevant until adulthood.

B. Persons with intellectual or psychosocial disabilities

Individuals with disabilities must not be presumed incapable of making decisions merely because of their diagnosis.

Moroccan law recognizes the importance of obtaining the participant's own consent when they are capable of expressing their wishes.

Researchers should therefore:

Provide accessible consent documents.

Use simplified explanations where appropriate.

Allow additional time for decision-making.

Avoid coercion by caregivers or institutions.

Respect refusal and withdrawal.

Obtain legally required representative consent where applicable.

This is particularly important in genetic research involving intellectual disabilities, neurodevelopmental disorders and inherited neurological diseases.

C. Economically disadvantaged communities

Poor communities may be vulnerable to undue influence when researchers offer financial incentives, free medical treatment or other benefits.

Article 9 of Law 28-13 restricts financial compensation to participants, allowing reimbursement of expenses and payment of additional costs arising from participation rather than direct or indirect financial rewards for participation.

This provision helps prevent economically disadvantaged individuals from accepting disproportionate research risks because of financial hardship.

Ma Loi

D. Pregnant women and breastfeeding mothers

Article 14 establishes restrictions on biomedical research involving pregnant women, women in childbirth and breastfeeding mothers, while allowing exceptional research under specified conditions.

Genetic research involving these groups requires particular attention to:

Maternal health.

Fetal safety.

Potential hereditary consequences.

The distinction between maternal and fetal genetic information.

The interests of the future child.

E. Hospitalized patients

Article 15 restricts recruitment of patients staying in public or private hospitals. Such patients may be approached only where comparable research cannot be conducted on another category of persons and the statutory conditions are satisfied.

The researcher must ensure that the patient's medical treatment is not compromised by the decision to participate or refuse.

F. Refugees, migrants and foreign nationals

An important issue arises under Article 3 of Law 28-13, which provides that a foreign national may not participate in biomedical research unless their situation complies with Moroccan legislation governing entry and residence.

This provision creates a significant legal issue for genetic studies involving refugees, undocumented migrants and displaced communities.

Researchers must distinguish between the legal conditions for participation and the ethical obligation to avoid exploitation or discrimination.

In particular, access to medical treatment should not be made conditional upon participation in genetic research.

Ma Loi+1

5. Informed consent and genetic research

Informed consent is one of the most important protections under Moroccan law.

Article 4 of Law 28-13 requires free, informed and express consent before biomedical research begins.

The participant must receive oral and written information in a language they understand, covering:

The objectives of the research.

The methodology and duration.

Foreseeable risks and constraints.

Expected benefits.

Available medical alternatives.

Rights under the legislation.

The possibility of obtaining assistance from another person to understand the information.

Article 5 recognizes the right to refuse participation or withdraw consent at any time. Article 6 requires written documentation of consent and its withdrawal.

Ma Loi+2

For genetic research, informed consent should additionally address:

Whether DNA will be used for whole-genome or targeted sequencing.

Whether incidental findings may be discovered.

Whether clinically significant findings will be communicated.

Whether biological samples will be stored.

Whether samples may be used in future research.

Whether genetic information will be transferred internationally.

Whether commercial entities may receive research results.

Whether relatives may be indirectly affected by the findings.

Example: A university conducts a genetic study of hereditary diseases in a disadvantaged rural Moroccan community. Participants agree to provide blood samples for research into a particular inherited disease. The university subsequently proposes to use the samples for ancestry research.

The original consent cannot automatically be treated as authorization for this unrelated secondary purpose. The institution must assess the scope of consent, the applicable data-protection requirements and the need for further authorization or consent.

6. Genetic privacy and protection against discrimination

Genetic information has characteristics that distinguish it from ordinary medical information.

It can reveal information about:

Biological relatives.

Family relationships.

Hereditary disease risks.

Ancestral origins.

Potential reproductive risks.

Future health conditions.

Under Law 09-08, genetic information is sensitive personal data. Its collection and processing must comply with the requirements applicable to sensitive information.

The CNDP is responsible for supervising the personal-data protection framework.

Three major legal issues arise.

First: Confidentiality. Researchers must prevent unauthorized disclosure of genetic information.

Second: Secondary use. Researchers must ensure that genetic information is not used for purposes incompatible with the original collection.

Third: International transfer. Cross-border transfer of genetic data must be assessed under the applicable requirements of Law 09-08, including its provisions concerning transfers outside Morocco.

These protections are particularly important when foreign universities, pharmaceutical companies and international genomic databases participate in Moroccan research projects.

BDJ+1

7. Relevant case laws and judicial precedents

An important qualification is necessary: I have not identified a reported Moroccan court judgment specifically deciding vulnerable-population recruitment in genetic research under Law 28-13.

Accordingly, the following are comparative judicial precedents. They provide useful legal reasoning but are not binding Moroccan judgments.

Case 1: S. and Marper v. United Kingdom (2008)

The European Court of Human Rights examined the indefinite retention of fingerprints and DNA profiles belonging to individuals who had not been convicted.

The Court found a violation of Article 8 of the European Convention on Human Rights, concerning respect for private life.

Relevance to Morocco:

The case illustrates why genetic information requires strong privacy protection. Researchers should not retain identifiable genetic information indefinitely without a lawful and justified purpose.

It is particularly relevant when research involves children, persons with disabilities and disadvantaged communities.

Case 2: Glass v. United Kingdom (2004)

This case concerned medical treatment administered to a child with severe disabilities despite opposition from his mother.

The European Court of Human Rights found a violation of Article 8 because the domestic authorities had failed to obtain appropriate judicial resolution of the disagreement.

Relevance to Morocco:

The judgment demonstrates the importance of respecting the rights of children with disabilities and addressing disagreements between healthcare professionals and legal representatives.

In genetic research, a parent's authorization should not be used to disregard the child's expressed refusal where the child is capable of expressing their wishes.

Case 3: V.C. v. Slovakia (2011)

The case concerned the sterilization of a Roma woman without valid informed consent.

The European Court of Human Rights found violations of Article 3 and Article 8 of the European Convention on Human Rights.

Relevance to Morocco:

The judgment demonstrates that vulnerable individuals must be protected from medical procedures performed without meaningful consent.

Its reasoning is relevant to genetic research involving marginalized communities, particularly where social disadvantage, limited medical literacy or institutional authority may undermine voluntary participation.

Case 4: Pretty v. United Kingdom (2002)

The case concerned personal autonomy and the right to make decisions concerning one's own life and bodily integrity.

Relevance to Morocco:

Although not a genetic-research case, it provides comparative reasoning about individual autonomy and dignity.

It supports the principle that genetic research should respect personal decision-making rather than treating participants merely as sources of biological material.

Case 5: Gaughran v. United Kingdom (2020)

The Court considered the retention of personal data, including fingerprints and DNA profiles, following a conviction.

It found that the retention regime violated Article 8 because it lacked adequate safeguards and proportionality.

Relevance to Morocco:

The case is useful when assessing long-term storage of genetic samples, retention periods, access restrictions and the proportionality of research databases.

Law Gratis+1

8. Research authorization and institutional accountability

Moroccan law establishes a regulatory procedure for biomedical research.

The principal requirements include:

Article 30 is particularly relevant to international genetic research. It restricts the transfer of biological samples abroad for analysis to situations where laboratories in Morocco cannot perform the relevant analysis to equivalent quality and good-practice standards.

This restriction is important when international universities or pharmaceutical companies wish to conduct genomic sequencing using samples collected from Moroccan communities.

Ma Loi+1

9. Recent regulatory development: Decree No. 2.26.223 of 2026

An important development must be considered when examining the current regulatory framework.

Morocco adopted Decree No. 2.26.223 of 30 April 2026, published in Official Gazette No. 7505 on 4 May 2026.

It amends and supplements Decree No. 2.20.326 of 5 April 2021, which implements Law No. 28-13.

The amendment modifies several implementing provisions, including Articles 5, 8, 10, 16, 20 and 22, and introduces additional provisions.

The Moroccan Government Council had previously approved the draft on 19 March 2026.

For genetic research involving vulnerable populations, researchers should therefore consult the amended implementing decree rather than relying exclusively on the original 2021 regulations.

Eastlaws+2

10. Major legal challenges

Despite the statutory protections, several challenges remain.

1. Inadequate understanding of genetic consent

Participants may understand that their blood is being collected but may not understand the implications of whole-genome sequencing or future data sharing.

2. Family privacy conflicts

One participant's genetic information may reveal hereditary information about siblings, parents and children. This creates difficult questions about confidentiality and disclosure.

3. Commercial exploitation

Foreign research organizations may obtain valuable genetic datasets from communities that receive limited direct benefits.

4. Digital security risks

Genetic databases may be vulnerable to unauthorized access, re-identification and misuse.

5. Unequal research participation

Researchers may disproportionately recruit poor or medically disadvantaged populations because they are easier to access.

6. Limited legal representation

People with disabilities and children may face difficulties exercising their rights where legal representatives or caregivers have conflicting interests.

7. International research inequality

Moroccan participants may contribute biological samples to international research projects without receiving adequate access to resulting diagnostic technologies, scientific findings or medical benefits.

11. Practical example: Genetic research involving rural Moroccan children

Suppose a Moroccan university and a foreign biotechnology company establish a research project investigating hereditary blood disorders among children in economically disadvantaged rural communities.

The project involves collecting blood samples, sequencing DNA and creating a genetic database.

The following legal safeguards would be necessary:

The research protocol must undergo the applicable regional ethics review.

The researchers must justify the inclusion of children.

Parents or legal representatives must provide the legally required consent.

Children capable of expressing their wishes must also be appropriately involved in the consent process.

The researchers must explain the purpose and foreseeable risks of genetic sequencing.

The collection and processing of genetic data must comply with Law 09-08 and CNDP requirements.

International sample transfers must comply with Article 30 of Law 28-13.

Commercial access to genetic information must be appropriately regulated.

The research institution must implement confidentiality and cybersecurity measures.

Participants must receive appropriate information about withdrawal, follow-up and relevant findings.

If the foreign company subsequently uses the genetic database for an unrelated commercial project, the legality of that use must be reassessed under the original consent, the research protocol and applicable data-protection rules.

The sponsor may also face responsibility under Article 34 if research-related injury is established.

12. International legal and ethical principles

Morocco's regulatory framework should also be considered alongside international instruments.

These instruments provide important interpretative and ethical guidance, subject to their respective legal status and applicability in Morocco.

13. Recommendations for strengthening Moroccan regulation

The following reforms would improve protection while allowing meaningful participation in genetic research.

A. Specific genetic-research consent rules

Morocco should develop more detailed rules governing genomic sequencing, secondary use, incidental findings and long-term biological sample storage.

B. Stronger protection for children

Research protocols should distinguish between childhood-onset conditions and genetic findings relevant only to adulthood.

C. Independent participant representation

Independent advocates should be available where vulnerable participants have difficulty understanding research procedures or where conflicts of interest arise.

D. Better protection against genetic discrimination

Clear safeguards should prevent genetic information from being improperly used in employment, insurance, education and other decisions.

E. International benefit-sharing

Foreign research institutions should establish transparent arrangements concerning local scientific participation, technology transfer, capacity building and access to research benefits.

F. Stronger cybersecurity

Genetic databases should have access controls, encryption, appropriate retention periods and procedures for responding to data breaches.

G. Improved judicial remedies

Participants should have effective avenues for seeking compensation, challenging unlawful data processing and reporting research misconduct.

14. Conclusion

The regulation of vulnerable population inclusion in genetic research in Morocco is based principally on Law No. 28-13 of 2015 and Law No. 09-08 of 2009.

Law 28-13 provides safeguards concerning informed consent, protection of minors and legally protected adults, research ethics committees, participant safety and sponsor liability. Law 09-08 establishes specific protection for genetic information as sensitive personal data.

The 2026 amendment to the implementing regulations through Decree No. 2.26.223 is also important when assessing current compliance.

The central legal challenge is achieving a balance between scientific progress, public-health interests, individual autonomy and protection against exploitation.

Morocco's legal framework therefore supports an approach in which vulnerable populations are neither automatically excluded from scientific advancement nor exposed to unjustified research risks.

The fundamental principle is that genetic research must respect human dignity, voluntary participation, informed consent, privacy and equitable distribution of scientific benefits.

15. Important legal references and research sources

Law No. 28-13 of 2015 – Protection of Persons Participating in Biomedical Research.

Decree No. 2.20.326 of 5 April 2021 – Implementing regulations.

Decree No. 2.26.223 of 30 April 2026 – Amendment to the implementing regulations.

Law No. 09-08 of 2009 – Protection of Personal Data.

Moroccan Constitution of 2011 – Articles 22, 24, 31 and 34.

UNESCO International Declaration on Human Genetic Data, 2003.

Convention on the Rights of the Child.

Convention on the Rights of Persons with Disabilities.

Useful primary and institutional sources:

Moroccan Ministry of Health – Medical practice regulations.

CNDP – Personal-data protection legislation.

Full text of Law No. 28-13.

Official legal text of Law No. 09-08.

Decree No. 2.26.223 of 2026.

Moroccan Government Council announcement, 19 March 2026.

Academic research note: The comparative court decisions discussed above should not be cited as Moroccan precedents. A definitive account of Moroccan case law would require verification of published Moroccan judgments specifically addressing genetic research, consent, privacy or biomedical experimentation.